RecruitingNCT05478694
Outcomes of Focal Ablation for Prostate Cancer
Prospective Single Institutional Study Evaluating the Outcomes for Patients Undergoing Ablative Therapies in the Management of Clinically Localized Prostate Cancer in the Primary and Salvage Setting
Sponsor
University of Texas Southwestern Medical Center
Enrollment
225 participants
Start Date
Feb 1, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.
Eligibility
Sex: MALEMin Age: 18 YearsMax Age: 90 Years
Inclusion Criteria5
- Men with histologically confirmed prostate adenocarcinoma diagnosed on prostate biopsy
- Men with histologically confirmed local recurrence of prostate cancer diagnosed on prostate biopsy and standard of care imaging excluding locoregional or metastatic disease
- Age 18-90 years.
- Life expectancy \> 1 year
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria3
- Anatomic abnormalities that do not allow for focal ablation
- Evidence of non-organ confined disease that is not feasible for ablation
- Has active urinary traction infection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05478694
Related Trials
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
64Cu-GRIP B in Patients With Advanced Malignancies
NCT058885321 location